Overview

Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response

Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
Phase I/IIClinical trial, proof of concept, double blind, and placebo-controlled, randomized 2:1 (MSCs: placebo), total sample size is 15 subjects
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Collaborator:
Iniciativa Andaluza en Terapias Avanzadas